Which Drug Will “Lead” in Reducing Cardiac Events Among Heart Failure Patients With Diabetes?
- 9 March 2020
- journal article
- editorial
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 75 (10), 1142-1144
- https://doi.org/10.1016/j.jacc.2019.12.062
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart FailureJournal of the American College of Cardiology, 2020
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionThe New England Journal of Medicine, 2019
- Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes MellitusJACC: Heart Failure, 2018
- Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes MellitusCirculation, 2018
- Effect of liraglutide, a glucagon‐like peptide‐1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double‐blind, randomised, placebo‐controlled trialEuropean Journal of Heart Failure, 2016
- Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection FractionJAMA, 2016
- Liraglutide and Cardiovascular Outcomes in Type 2 DiabetesThe New England Journal of Medicine, 2016
- 2013 ACCF/AHA Guideline for the Management of Heart FailureJournal of the American College of Cardiology, 2013